硝苯地平藥物市場：依劑型、適應症、通路及地區分類

硝苯地平藥物市場規模預計在 2025 年為 12.567 億美元，預計到 2032 年將達到 23.57 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 9.4%。

硝苯地平是一種鈣通道阻斷劑，用於治療高血壓和心絞痛引起的胸痛。鈣通道阻斷劑透過放鬆動脈壁肌肉，增加心臟的血液和氧氣供應來發揮作用。硝苯地平於1983年首次核准用於醫療用途。硝苯地平透過阻斷心臟和動脈肌肉細胞中的鈣離子通道來發揮作用。這使得血管擴張，從而降低血壓並減輕心臟負擔。硝苯地平有短效和長效錠劑形式，已被證明能有效控制血壓並緩解全球數百萬人的胸痛。

市場動態

在預計預測期內，患有高血壓和心血管疾病的人數不斷增加以及老齡化人口不斷增加是推動全球硝苯地平藥物市場成長的關鍵因素。

此外，市場參與企業正熱衷於推出新的硝苯地平產品，預計這將在預測期內促進全球硝苯地平市場的成長。例如，學名藥開發商AVET Pharmaceuticals於2019年9月18日推出了硝苯地平軟膠囊。該產品有10毫克和20毫克兩種規格可供選擇。本產品是鈣拮抗劑Procardia的AB級學名藥，進一步豐富了Avet強大的非專利口服固體製劑製劑產品組合。

然而，預計專利到期、監管挑戰、副作用、替代療法的可用性、治療模式的轉變以及定價壓力將在預測期內阻礙全球硝苯地平藥物市場的成長。

研究的主要特點

• 本報告對全球硝苯地平藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率(CAGR)。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
• 全球硝苯地平劑量市場的主要企業會根據以下參數進行分析，例如公司亮點、產品系列、關鍵亮點、財務績效和策略。
• 預計本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球硝苯地平藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過全球硝苯地平藥物市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• 一致的機會圖（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 合併、收購和合作

4. 全球硝苯地平藥物市場-冠狀病毒（COVID-19）大流行的影響

• COVID-19流行病學
• 供需側分析
• 經濟影響

5. 2020 年至 2032 年全球硝苯地平藥物市場（以劑型分類）

• 介紹
• 錠劑
• 緩釋片
• 膠囊
• 其他（舌下片、噴霧劑、貼片等）

6. 全球硝苯地平藥物市場（依適應症分類），2020 年至 2032 年

• 介紹
• 高血壓
• 心絞痛
• 雷諾現象
• 其他（早產、血管痙攣性疾病等）

7. 全球硝苯地平藥物市場（依通路分類），2020-2032 年

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

8. 2020 年至 2032 年按地區分類的全球硝苯地平藥物市場

• 介紹
• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中部非洲

第9章 競爭態勢

• 公司簡介
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Mylan NV
  • Sanofi SA
  • Johnson & Johnson
  • GlaxoSmithKline plc.
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH（諾華公司的一個部門）
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Apotex Inc.

第 10 章 章節

• 參考
• 調查方法
• 關於出版商

Nifedipine Medication Market is estimated to be valued at USD 1,256.7 Mn in 2025 and is expected to reach USD 2,357.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.

Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.

Market Dynamics:

A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.

Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet's robust portfolio of generic oral solid products.

However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global nifedipine medication market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nifedipine medication market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited , Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division) Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd, and Apotex
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nifedipine medication market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nifedipine medication market

Global Nifedipine Medication Market Detailed Segmentation:

• By Dosage Form:
  • Tablets
  • Extended-release Tablets
  • Capsules
  • Others (Sublingual tablets/spray, Patches and Others)
• By Indication:
  • Hypertension
  • Angina Pectoris
  • Raynaud's Phenomenon
  • Others (Pre-term labor, vasospastic conditions and Others)
• By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (a Novartis division)
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Dosage Form
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Nifedipine Medication Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Nifedipine Medication Market, By Dosage Form, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Extended-Release Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Capsules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Sublingual tablets/spray, Patches and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Nifedipine Medication Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Angina Pectoris
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Raynaud's Phenomenon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Pre-term labor, vasospastic conditions and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Nifedipine Medication Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. 8. Global Nifedipine Medication Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Sub-region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Company Profile
  • Pfizer Inc
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • AstraZeneca PLC
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Teva Pharmaceutical Industries Ltd
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sanofi S.A.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Johnson & Johnson
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • GlaxoSmithKline plc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Lupin Limited
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sandoz International GmbH (a Novartis division)
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Dr. Reddy's Laboratories Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Torrent Pharmaceuticals Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Apotex Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Analyst Views

10. Section

• References
• Research Methodology
• About us